Exercise and Diet Effects in Reducing Cardiovascular Risk in Kidney Transplant Recipients
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 28, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how exercise and diet can help reduce the risk of heart problems in people who have received a kidney transplant. Over three years, the study will compare a group of kidney transplant patients who will follow a personalized exercise and diet plan with another group that receives standard care. The goal is to see if the tailored approach can lower cardiovascular risk more effectively.
To participate in this study, you need to be a kidney transplant recipient between the ages of 30 and 69, and you should be in stable health for at least six months after your transplant. The study is currently recruiting participants, and if you join, you'll work with healthcare professionals to follow the exercise and diet plan. This could be a great opportunity to improve your health and well-being while contributing to important research on kidney transplant care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinically stabilised male and female kidney transplant patients (assessment by the referring transplant centre)
- • Minimum age, 30 years;
- • Maximum age, 69 years;
- • Period since transplantation: from 6 months (subject to clinical stability being achieved) to 10 years;
- • Organ function: eGFR (CKD-EPI formula) ≥ 30 mL/min/1.73m ;2
- • Obtaining informed consent;
- Exclusion Criteria:
- • Patients unable to follow the prescription,
- • Recent acute cardiovascular event (\< 2 months),
- • Unstable angina,
- • Hyperkinetic/hypokinetic arrhythmias not controlled by therapy, and with signs of haemodynamic impairment,
- • Severe aortic stenosis,
- • Heart failure NYHA class III-IV, FE \< 40%,
- • Acute illnesses that limit physical activity,
- • Severe hypertension (basal BP ≥200/110 mm Hg),
- • Neuro-musculo-skeletal pathologies that may be aggravated by exercise,
- • Patients unwilling to change lifestyle;
- • Any form of substance abuse, psychiatric disorder or condition that, according to the investigator, can complicate communication between doctor and patient;
- • Pregnant women.
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Giuseppe Tarantino, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported